Cornelis J. A. Punt

发表

Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients

W. Oyen, C. Figdor, C. Punt, 2009, Clinical Cancer Research.

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.

C. Figdor, C. Punt, G. Adema, 2005, Blood.

Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.

W. Oyen, C. Figdor, C. Punt, 1999, Cancer research.

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.

A. Eggermont, C. Punt, P. Patel, 2006, European journal of cancer.

Maximizing dendritic cell migration in cancer immunotherapy

C. Figdor, C. Punt, Pauline Verdijk, 2008, Expert opinion on biological therapy.

Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination

C. Punt, P. Mulders, S. Teerenstra, 2011, Clinical Cancer Research.

Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells.

C. Figdor, C. Punt, G. Adema, 2010, Blood.

Dendritic cell vaccines in melanoma: from promise to proof?

C. Figdor, G. Adema, E. Aarntzen, 2008, Critical reviews in oncology/hematology.

Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters

C. Punt, G. Adema, I. Joosten, 2012, Cancer Immunology, Immunotherapy.

Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production.

C. Figdor, C. Punt, G. Adema, 2008, Blood.

In vivo imaging of therapy-induced anti-cancer immune responses in humans

C. Radu, M. Srinivas, E. Aarntzen, 2012, Cellular and Molecular Life Sciences.

Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.

N. Naus, A. de Klein, W. Gerritsen, 2016, Ophthalmology.

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

C. Figdor, C. Punt, R. Koornstra, 2020, Cancer Immunology, Immunotherapy.